In this review, we discuss three CDK4/6 inhibitors with different clinical trial results and various resistance mechanisms, aiming to help identify novel clinical therapeutic targets to improve endocrine therapy resistance and provide possible strategies to overcome resistance to CDK4/6 inhibitors in advanced luminal breast cancer. The gene discussed is CDK4; the disease is breast cancer.